← Back to headlines
AbbVie's Venclexta-Acalabrutinib Combo Approved for CLL
AbbVie has received FDA approval for its Venclexta-acalabrutinib combination therapy as a first-line treatment for chronic lymphocytic leukemia (CLL).
20 Feb, 11:01 — 20 Feb, 11:01
Sources
Showing 1 of 1 sources
Related Stories
Irish Health Agency Fined €645,000 for Storing Records in Derelict Sites
1h ago
New Urine Test Detects Over 90 Percent of Bladder Cancer Cases
2h ago
Swimmer Hospitalized Following Suspected Shark Attack in Massachusetts
5h ago
Wellington Clinics Suspends Kidney Transplants Amid Organ Harvesting Probe
11h ago